Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IONIS TMPRSS6-Lrx · 1 trial · 1 indication
The safety and tolerability of single and multiple doses of IONIS TMPRSS6-Lrx will be assessed by determining the incidence, severity, and dose relationship of adverse events that are related to treatment with IONIS TMPRSS6-Lrx
| Arm | Type | Description |
|---|---|---|
| IONIS TMPRSS6-Lrx | EXPERIMENTAL | Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously |
| Placebo | PLACEBO_COMPARATOR | Saline .9% |
| Name | Type | Description |
|---|---|---|
| IONIS TMPRSS6-Lrx | DRUG | Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously |
| Placebo | OTHER | Saline .9% |
Inclusion Criteria: * Must have given written informed consent and be able to comply with all study requirements * Healthy males or females aged 18-65 inclusive at the time of Informed Consent * Females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal * Male...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. | AGIO | 5 | PHASE3 | Mitapivat |
| Bristol-Myers Squibb Company | BMY | 6 | PHASE3 | Luspatercept |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | CTX001 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | Etavopivat A, Etavopivat B, Etavopivat C |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN7999 |
| ICON Plc | ICLR | 1 | PHASE2 | SP-420 |
| Editas Medicine, Inc. | EDIT | 2 | PHASE1 | EDIT-301 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
IONIS TMPRSS6-Lrx is an investigational small molecule being developed for thalassemia, a blood disorder. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its potential role in managing this condition, though its efficacy and safety are still being evaluated.
IONIS TMPRSS6-Lrx is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's safety and tolerability in healthy volunteers as part of early-stage research.
IONIS TMPRSS6-Lrx is in Phase 1 clinical development. A Phase 1 trial has been completed, which focused on assessing the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. The drug remains investigational and has not received regulatory approval for any indication.
IONIS TMPRSS6-Lrx has one completed clinical trial, registered under NCT03165864. This Phase 1 study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug when administered subcutaneously to healthy volunteers. The trial was randomized, double-blind, and placebo-controlled, enrolling 36 participants in Australia.
Yes, IONIS TMPRSS6-Lrx is also known as ISIS 702843. The completed clinical trial NCT03165864 used the name ISIS 702843 to refer to the drug. Both names refer to the same investigational compound being developed by Ionis Pharmaceuticals for thalassemia.